乌司他丁联合阿托伐他汀对慢性阻塞性肺病急性加重期的临床疗效观察

发布时间：2018-01-04 05:00

本文关键词：乌司他丁联合阿托伐他汀对慢性阻塞性肺病急性加重期的临床疗效观察　出处：《浙江大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的观察乌司他丁联合阿托伐他汀对慢性阻塞性肺病急性加重期(acute exacerbation of chronic obstructive pulmonary disease, AECOPD)患者的临床疗效。方法选取杭州市余杭区第三人民医院AECOPD患者211例,分为常规治疗组、阿托伐他汀治疗组,阿托伐他汀联合乌司他丁治疗组,分别监测患者症状恢复情况,血气分析,肺功能分析,中性粒细胞数目,血清C反应蛋白(C-reactive protein, CRP)、白介素6 (interleukin -6, IL-6)浓度,评估患者临床恢复情况。结果阿托伐他汀联合乌司他丁治疗可以显著提高AECOPD患者1周临床有效率,缩短住院时间,升高氧分压,降低二氧化碳分压,改善肺功能(有效升高FEV1%及FEV1/FVC%)并能显著减轻患者炎症状态(中性粒细胞计数下降、CRP、IL-6浓度降低)。结论阿托伐他汀联合乌司他丁作为AECOPD有效且安全的治疗手段,在临床中有广泛的应用前景,并值得临床推广。
[Abstract]:Objective to investigate the effects of ulinastatin combined with atorvastatin on acute exacerbation of chronic obstructive pulmonary disease (acute exacerbation of chronic obstructive pulmonary disease, AECOPD) in patients with clinical efficacy. Methods the patients with AECOPD in Hangzhou City Third People's Hospital of Yuhang District in 211 cases, divided into routine treatment group, atorvastatin group, atorvastatin combined with ulinastatin he d treatment group were monitoring the recovery of clinical symptoms, blood gas analysis, pulmonary function analysis, the number of neutrophil, serum C reactive protein (C-reactive protein, CRP), interleukin 6 (interleukin, -6, IL-6) concentration, evaluation of patients with clinical recovery. Results Atorvastatin Combined with ulinastatin in the treatment of AECOPD patients 1 weeks of clinical efficiency improved significantly, shorten the hospitalization time, the increase of the oxygen partial pressure, reduce carbon dioxide partial pressure, improve lung function (effective increase in FEV1% and FEV1/FVC%) and significantly Reduce the inflammatory state of patients (neutrophil count decreased, CRP and IL-6 concentration decreased). Conclusion Atorvastatin Combined with ulinastatin is an effective and safe treatment for AECOPD. It has wide application prospects in clinical practice, and is worthy of clinical promotion.

【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R563.9

【参考文献】